The latest price target for MiMedx Group (NASDAQ:MDXG) was reported by Cantor Fitzgerald on August 1, 2024. The analyst firm set a price target for $11.00 expecting MDXG to rise to within 12 months (a possible 19.11% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for MiMedx Group (NASDAQ:MDXG) was provided by Cantor Fitzgerald, and MiMedx Group reiterated their overweight rating.

There is no last upgrade for MiMedx Group

There is no last downgrade for MiMedx Group.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MiMedx Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MiMedx Group was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.

While ratings are subjective and will change, the latest MiMedx Group (MDXG) rating was a reiterated with a price target of $11.00 to $11.00. The current price MiMedx Group (MDXG) is trading at is $9.24, which is out of the analyst’s predicted range.